Ligand slashes staff in restructuring effort

In an effort to transform itself into an R&D focused biotech company, Ligand Pharmaceuticals has announced that it is cutting about three out of every four of its remaining workers. The move will reduce its workforce to 85 employees from the 352 on payroll several months ago. Senior execs including its CFO are on the way out and Ligand will shutter its U.K. operation. New CEO John Higgins says the move is difficult, but the company needs to restructure, reducing annual expenses by $20 million to $22 million. The changes are being driven by Third Point, a hedge fund that acquired a major stake in Ligand following a financial scandal that forced the company to restate its financial reports. Ligand sold its approved drugs last summer for $470 million along with an ongoing stream of royalties. Ligand says it will fit into one facility after the restructuring, allowing it to sublet the remaining space.

- see Ligand's press release on the cuts
- read the report from the San Diego Union Tribune

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.